{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:40:47Z","timestamp":1793796047690,"version":"4.6.1"},"reference-count":135,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antithrombotic therapy is essential after coronary artery bypass graft surgery to reduce ischaemic events and prevent graft occlusion. Although aspirin remains the most commonly used agent, in higher-risk patients, dual antiplatelet therapy or combining antiplatelet therapy with oral anticoagulation may be beneficial, but this increases bleeding risk. The choice of antithrombotic therapy should be tailored to each patient, based on their ischaemic and bleeding risks, and regularly reassessed. Here, the scientific evidence underlying the key aspects of the choice of antithrombotic therapy after coronary artery bypass grafting is reviewed. Consensus statements for best clinical practice are provided and areas requiring further research are highlighted.<\/jats:p>","DOI":"10.1093\/ejcts\/ezaf243","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T07:01:37Z","timestamp":1756537297000},"source":"Crossref","is-referenced-by-count":6,"title":["Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS)"],"prefix":"10.1093","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4669-9841","authenticated-orcid":false,"given":"Sigrid","family":"Sandner","sequence":"first","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna , Spitalgasse 23 , Vienna 1090,","place":["Austria"]},{"name":"Department of Cardiothoracic Surgery, Weill Cornell Medicine , 525 East 68th Street , New York, NY 10065,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4680-0815","authenticated-orcid":false,"given":"Mario","family":"Gaudino","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Weill Cornell Medicine , 525 East 68th Street , New York, NY 10065,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Institute of Clinical Science, Oslo University , Oslo,","place":["Norway"]},{"name":"Institute of Clinical Sciences, Karolinska Institute, Danderyd Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-0664","authenticated-orcid":false,"given":"Giorgia","family":"Bonalumi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Centro Cardiologico Monzino IRCCS , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Bonaros","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Medical University of Innsbruck , Innsbruck,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Czerny","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, University Heart Center Freiburg\u2014Bad Krozingen, Faculty of Medicine, Albert Ludwigs University Freiburg , Freiburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-2295","authenticated-orcid":false,"given":"Anders","family":"Jeppsson","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Sahlgrenska University Hospital , Gothenburg,","place":["Sweden"]},{"name":"Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-9011","authenticated-orcid":false,"given":"Milan","family":"Milojevic","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute , Belgrade,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-0935","authenticated-orcid":false,"given":"Alexander","family":"Niessner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna , Vienna,","place":["Austria"]},{"name":"2nd Department of Medicine with Cardiology and Intensive Care Medicine, Vienna Healthcare Group Clinic Landstrasse , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parolari","sequence":"additional","affiliation":[{"name":"Department of Universitary Cardiac Surgery, IRCCS Policlinico San Donato , Milan,","place":["Italy"]},{"name":"Department of Biomedical Sciences for Health, University of Milan , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-0099","authenticated-orcid":false,"given":"Patrick","family":"Sulzgruber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Thielmann","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Center, University of Duisburg-Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wassmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology , Pasing, Munich,","place":["Germany"]},{"name":"Faculty of Medicine, University of Saarland , Homburg\/Saar,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-0618","authenticated-orcid":false,"given":"Alicja","family":"Zientara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, University Heart Center Freiburg\u2014Bad Krozingen, Faculty of Medicine, Albert Ludwigs University Freiburg , Freiburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen , Essen,","place":["Germany"]},{"name":"Department of Medicine and Research Center, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , Montreal, Quebec,","place":["Canada"]},{"name":"Department of Integrative Physiology, Baylor College of Medicine , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"2026071011565657600_ezaf243-B1","doi-asserted-by":"publisher","first-page":"ezae355","DOI":"10.1093\/ejcts\/ezae355","article-title":"2024 EACTS guidelines on perioperative medication in adult cardiac surgery","volume":"67","author":"Jeppsson","year":"2024","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026071011565657600_ezaf243-B2","doi-asserted-by":"publisher","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"2026071011565657600_ezaf243-B3","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B4","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jacc.2018.11.053","article-title":"PCI and CABG for treating stable coronary artery disease: JACC review topic of the week","volume":"73","author":"Doenst","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1161\/CIRCULATIONAHA.117.027597","article-title":"Mechanisms, consequences, and prevention of coronary graft failure","volume":"136","author":"Gaudino","year":"2017","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","article-title":"Aspirin","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026071011565657600_ezaf243-B9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"2026071011565657600_ezaf243-B12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071011565657600_ezaf243-B13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (section III). position paper of the ESC working group on thrombosis\u2013task force on anticoagulants in heart disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026071011565657600_ezaf243-B14","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026071011565657600_ezaf243-B15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurheartj\/ehw525","article-title":"Trade-off of myocardial infarction vs. Bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.hjc.2018.06.012","article-title":"Health-related quality of life after adverse bleeding events associated with antithrombotic drug therapy\u2014a systematic review","volume":"60","author":"Res","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"2026071011565657600_ezaf243-B17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1160\/TH16-09-0721","article-title":"Prediction of severe bleeding after coronary surgery: the WILL-BLEED risk score","volume":"117","author":"Biancari","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026071011565657600_ezaf243-B18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1160\/TH17-10-0702","article-title":"External validation of the WILL-BLEED risk score","volume":"118","author":"Biancari","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026071011565657600_ezaf243-B19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.23736\/S0021-9509.20.11048-6","article-title":"Predictive scores for major bleeding after coronary artery bypass surgery in low operative risk patients","volume":"61","author":"Salsano","year":"2020","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"2026071011565657600_ezaf243-B20","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2026071011565657600_ezaf243-B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ejcts\/ezx334\"&gt;https:\/\/doi.org\/10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026071011565657600_ezaf243-B23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/ehjcvp\/pvae060","article-title":"The four-item PRECISE-DAPT score identifies coronary artery bypass grafting patients with increased risk for post-discharge major bleeding","volume":"11","author":"Enstrom","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026071011565657600_ezaf243-B24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ehjcvp\/pvad063","article-title":"External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis","volume":"9","author":"Munafo","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026071011565657600_ezaf243-B25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B26","doi-asserted-by":"publisher","first-page":"e129\u201350","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B27","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1016\/j.jcin.2024.08.027","article-title":"International consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update","volume":"17","author":"Angiolillo","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"2026071011565657600_ezaf243-B28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"2026071011565657600_ezaf243-B29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. Potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/eurheartj\/ehv381","article-title":"Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study","volume":"37","author":"Hansson","year":"2016","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/ejcts\/ezw149","article-title":"Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment","volume":"50","author":"Tomsic","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026071011565657600_ezaf243-B32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/hrt.2004.058396","article-title":"Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis","volume":"92","author":"Purkayastha","year":"2006","journal-title":"Heart"},{"key":"2026071011565657600_ezaf243-B33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B34","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/bja\/aeu315","article-title":"Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery","volume":"113","author":"Ranucci","year":"2014","journal-title":"Br J Anaesth"},{"key":"2026071011565657600_ezaf243-B36","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.jacc.2010.03.108","article-title":"Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery","volume":"56","author":"Kwak","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/bja\/aew189","article-title":"Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study","volume":"117","author":"Malm","year":"2016","journal-title":"Br J Anaesth"},{"key":"2026071011565657600_ezaf243-B38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.athoracsur.2010.09.022","article-title":"Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines","volume":"91","author":"Ranucci","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"2026071011565657600_ezaf243-B39","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/j.1538-7836.2011.04419.x","article-title":"Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses","volume":"9","author":"Storey","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2026071011565657600_ezaf243-B40","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.athoracsur.2016.05.003","article-title":"Does platelet reactivity predict bleeding in patients needing urgent coronary artery bypass grafting during dual antiplatelet therapy?","volume":"102","author":"Mahla","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"2026071011565657600_ezaf243-B41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists C","year":"2002","journal-title":"BMJ"},{"key":"2026071011565657600_ezaf243-B42","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists C","year":"2009","journal-title":"Lancet"},{"key":"2026071011565657600_ezaf243-B43","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa020798","article-title":"Aspirin and mortality from coronary bypass surgery","volume":"347","author":"Mangano","year":"2002","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B44","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/eurheartj\/ehz714","article-title":"Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry","volume":"41","author":"Bjorklund","year":"2020","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B45","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B46","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B47","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/1010-7940(93)90155-5","article-title":"Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis","volume":"7","author":"Fremes","year":"1993","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026071011565657600_ezaf243-B49","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1569-9293(03)00181-6","article-title":"Does aspirin 6 h after coronary artery bypass grafting optimise graft patency?","volume":"2","author":"Musleh","year":"2003","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026071011565657600_ezaf243-B50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cpt.702","article-title":"On-pump cardiac surgery enhances platelet renewal and impairs aspirin pharmacodynamics: effects of improved dosing regimens","volume":"102","author":"Cavalca","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026071011565657600_ezaf243-B51","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jth.13667","article-title":"Once versus twice daily aspirin after coronary bypass surgery: a randomized trial","volume":"15","author":"Paikin","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2026071011565657600_ezaf243-B52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1160\/TH14-11-0922","article-title":"Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects","volume":"114","author":"Polzin","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026071011565657600_ezaf243-B53","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/bja\/aev164","article-title":"Aspirin and coronary artery surgery: a systematic review and meta-analysis","volume":"115","author":"Hastings","year":"2015","journal-title":"Br J Anaesth"},{"key":"2026071011565657600_ezaf243-B54","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/icvts\/ivw317","article-title":"What is the impact of preoperative aspirin administration on patients undergoing coronary artery bypass grafting?","volume":"24","author":"Aboul-Hassan","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026071011565657600_ezaf243-B55","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"2026071011565657600_ezaf243-B56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B57","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/jama.2018.3197","article-title":"Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial","volume":"319","author":"Zhao","year":"2018","journal-title":"JAMA"},{"key":"2026071011565657600_ezaf243-B58","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/eurheartj\/ehz185","article-title":"Randomized trial of ticagrelor vs. Aspirin in patients after coronary artery bypass grafting: the TiCAB trial","volume":"40","author":"Schunkert","year":"2019","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12893-015-0096-z","article-title":"Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials","volume":"15","author":"Verma","year":"2015","journal-title":"BMC Surg"},{"key":"2026071011565657600_ezaf243-B60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijcard.2018.07.083","article-title":"Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: an updated meta-analysis","volume":"269","author":"Cardoso","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026071011565657600_ezaf243-B61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/heartjnl-2023-323097","article-title":"Optimal antiplatelet strategy following coronary artery bypass grafting: a meta-analysis","volume":"110","author":"Agrawal","year":"2024","journal-title":"Heart"},{"key":"2026071011565657600_ezaf243-B62","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/eurheartj\/ehab096","article-title":"The association between coronary graft patency and clinical status in patients with coronary artery disease","volume":"42","author":"Gaudino","year":"2021","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B63","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/CIRCULATIONAHA.123.064090","article-title":"Graft failure after coronary artery bypass grafting and its association with patient characteristics and clinical events: a pooled individual patient data analysis of clinical trials with imaging follow-up","volume":"148","author":"Gaudino","year":"2023","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B64","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jacc.2024.04.046","article-title":"Coronary artery bypass graft failure in women: incidence and clinical implications","volume":"84","author":"Sandner","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B65","doi-asserted-by":"publisher","first-page":"l5476","DOI":"10.1136\/bmj.l5476","article-title":"Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis","volume":"367","author":"Solo","year":"2019","journal-title":"BMJ"},{"key":"2026071011565657600_ezaf243-B66","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jama.2022.11966","article-title":"Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: a systematic review and meta-analysis","volume":"328","author":"Sandner","year":"2022","journal-title":"JAMA"},{"key":"2026071011565657600_ezaf243-B67","doi-asserted-by":"publisher","first-page":"e075707","DOI":"10.1136\/bmj-2023-075707","article-title":"Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial","volume":"385","author":"Zhu","year":"2024","journal-title":"BMJ"},{"key":"2026071011565657600_ezaf243-B68","doi-asserted-by":"publisher","first-page":"q1083","DOI":"10.1136\/bmj.q1083","article-title":"Dual antiplatelet therapy after coronary artery bypass surgery","volume":"385","author":"Sandner","year":"2024","journal-title":"BMJ"},{"key":"2026071011565657600_ezaf243-B69","doi-asserted-by":"publisher","first-page":"E305","DOI":"10.25270\/jic\/20.00321","article-title":"A randomized controlled trial of prasugrel for prevention of early saphenous vein graft thrombosis","volume":"32","author":"Danek","year":"2020","journal-title":"J Invasive Cardiol"},{"key":"2026071011565657600_ezaf243-B70","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B71","doi-asserted-by":"publisher","first-page":"e9\u2013119","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"2026071011565657600_ezaf243-B73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jacc.2018.10.048","article-title":"Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study","volume":"73","author":"Lamy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction","volume":"90","author":"Merlini","year":"1994","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B75","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B76","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B77","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B78","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B79","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/ehjcvp\/pvaa080","article-title":"Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. Stable ischaemic heart disease after coronary artery bypass grafting","volume":"7","author":"Choi","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026071011565657600_ezaf243-B80","doi-asserted-by":"crossref","first-page":"e2122597","DOI":"10.1001\/jamanetworkopen.2021.22597","article-title":"Comparison of midterm outcomes associated with aspirin and ticagrelor vs aspirin monotherapy after coronary artery bypass grafting for acute coronary syndrome","volume":"4","author":"Bjorklund","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026071011565657600_ezaf243-B81","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B82","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/eurheartj\/ehae654","article-title":"Intra-operative and post-operative management of conduits for coronary artery bypass grafting: a clinical consensus statement of the European Society of Cardiology working group on cardiovascular surgery and the European association for cardiothoracic surgery coronary task force","volume":"46","author":"Sandner","year":"2024","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B84","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/eurheartj\/ehad019","article-title":"Postoperative atrial fibrillation: from mechanisms to treatment","volume":"44","author":"Gaudino","year":"2023","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B85","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1093\/eurheartj\/ehae267","article-title":"Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis","volume":"45","author":"van de Kar","year":"2024","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B86","doi-asserted-by":"publisher","first-page":"e017966","DOI":"10.1161\/JAHA.120.017966","article-title":"New-onset atrial fibrillation after coronary artery bypass grafting and long-term outcome: a populationbased nationwide study from the SWEDEHEART registry","volume":"10","author":"Taha","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026071011565657600_ezaf243-B87","doi-asserted-by":"publisher","first-page":"e241537","DOI":"10.1001\/jamanetworkopen.2024.1537","article-title":"Recurrence of atrial fibrillation in patients with new-onset postoperative atrial fibrillation after coronary artery bypass grafting","volume":"7","author":"Herrmann","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026071011565657600_ezaf243-B88","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cjca.2021.01.018","article-title":"One ring to rule them all: continuous monitoring of patients with secondary atrial fibrillation points to a unifying underlying mechanism","volume":"37","author":"Aguilar","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026071011565657600_ezaf243-B89","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1161\/STROKEAHA.118.023921","article-title":"Perioperative\/postoperative atrial fibrillation and risk of subsequent stroke and\/or mortality","volume":"50","author":"Lin","year":"2019","journal-title":"Stroke"},{"key":"2026071011565657600_ezaf243-B90","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.athoracsur.2020.05.104","article-title":"Postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis","volume":"111","author":"Eikelboom","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"2026071011565657600_ezaf243-B91","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jtcvs.2021.03.077","article-title":"Atrial fibrillation after cardiac surgery: a systematic review and meta-analysis","volume":"165","author":"Caldonazo","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026071011565657600_ezaf243-B92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1001\/jamacardio.2018.0405","article-title":"Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation","volume":"3","author":"Butt","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026071011565657600_ezaf243-B93","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.hroo.2022.06.003","article-title":"Anticoagulation in new-onset postoperative atrial fibrillation: an analysis from the society of thoracic surgeons adult cardiac surgery database","volume":"3","author":"Riad","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"2026071011565657600_ezaf243-B94","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.hroo.2021.05.001","article-title":"The contribution of intermittent handheld electrocardiogram and continuous electrocardiogram monitoring with an implantable loop recorder to detect incident and recurrent atrial fibrillation during 1 year after coronary artery bypass graft surgery: a prospective cohort study","volume":"2","author":"Sandgren","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"2026071011565657600_ezaf243-B95","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.117.028845","article-title":"Subclinical atrial fibrillation in older patients","volume":"136","author":"Healey","year":"2017","journal-title":"Circulation"},{"key":"2026071011565657600_ezaf243-B96","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026071011565657600_ezaf243-B97","doi-asserted-by":"publisher","first-page":"e024703","DOI":"10.1161\/JAHA.121.024703","article-title":"Stroke risk stratification in patients with postoperative atrial fibrillation after coronary artery bypass grafting","volume":"11","author":"Taha","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026071011565657600_ezaf243-B98","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bja.2022.05.010","article-title":"Direct oral anticoagulants in atrial fibrillation following cardiac surgery: a systematic review and meta-analysis with trial sequential analysis","volume":"129","author":"Koh","year":"2022","journal-title":"Br J Anaesth"},{"key":"2026071011565657600_ezaf243-B99","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1053\/j.semtcvs.2021.05.011","article-title":"Safety of direct oral anticoagulants compared to warfarin for atrial fibrillation after cardiac surgery: a systematic review and meta-analysis","volume":"34","author":"Hage","year":"2022","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2026071011565657600_ezaf243-B100","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.xjon.2023.05.006","article-title":"Rivaroxaban versus warfarin in postoperative atrial fibrillation: cost-effectiveness analysis in a single-center, randomized, and prospective trial","volume":"15","author":"Pereira","year":"2023","journal-title":"JTCVS Open"},{"key":"2026071011565657600_ezaf243-B101","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.athoracsur.2020.12.031","article-title":"Non-vitamin K antagonist oral anticoagulant vs warfarin for post cardiac surgery atrial fibrillation","volume":"112","author":"Nauffal","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"2026071011565657600_ezaf243-B102","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026071011565657600_ezaf243-B103","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jocs.12074","article-title":"Dual antiplatelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis","volume":"28","author":"Deo","year":"2013","journal-title":"J Card Surg"},{"key":"2026071011565657600_ezaf243-B104","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.athoracsur.2024.04.010","article-title":"The current state of hybrid coronary revascularization","volume":"118","author":"Willard","year":"2024","journal-title":"Ann Thorac Surg"},{"key":"2026071011565657600_ezaf243-B105","doi-asserted-by":"publisher","first-page":"e009565","DOI":"10.1161\/CIRCINTERVENTIONS.120.009565","article-title":"One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients","volume":"13","author":"Kandzari","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2026071011565657600_ezaf243-B106","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B107","doi-asserted-by":"publisher","first-page":"ezae271","DOI":"10.1093\/ejcts\/ezae271","article-title":"Hybrid coronary revascularization: position paper of the European Society of Cardiology working group on cardiovascular surgery and European association of percutaneous cardiovascular interventions","volume":"66","author":"Thielmann","year":"2024","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026071011565657600_ezaf243-B108","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jacc.2008.10.011","article-title":"Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory\/operating room","volume":"53","author":"Zhao","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B109","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jacc.2013.04.007","article-title":"One-stop hybrid coronary revascularization versus coronary artery bypass grafting and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: 3-year follow-up results from a single institution","volume":"61","author":"Shen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B110","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jtcvs.2008.02.081","article-title":"Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up","volume":"136","author":"Kiaii","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026071011565657600_ezaf243-B111","doi-asserted-by":"publisher","first-page":"768860","DOI":"10.3389\/fsurg.2021.768860","article-title":"Clopidogrel loading dose 300 vs. 600mg in patients undergoing one-stop hybrid coronary revascularization: a prospective single-center randomized pilot study","volume":"8","author":"Guo","year":"2021","journal-title":"Front Surg"},{"key":"2026071011565657600_ezaf243-B112","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/icvts\/ivu157","article-title":"Adjunct coronary endarterectomy increases myocardial infarction and early mortality after coronary artery bypass grafting: a meta-analysis","volume":"19","author":"Soylu","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026071011565657600_ezaf243-B113","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.athoracsur.2022.01.067","article-title":"Coronary endarterectomy: analysis of the society of thoracic surgeons adult cardiac surgery database","volume":"114","author":"Kelly","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"2026071011565657600_ezaf243-B114","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/icvts\/ivx045","article-title":"Coronary endarterectomy with coronary artery bypass graft decreases graft patency compared with isolated coronary artery bypass graft: a meta-analysis","volume":"25","author":"Song","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026071011565657600_ezaf243-B115","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0022-5223(19)33939-X","article-title":"A study of the sequential morphologic changes after manual coronary endarterectomy","volume":"102","author":"Walley","year":"1991","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026071011565657600_ezaf243-B116","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/icvts\/ivw351","article-title":"Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications","volume":"24","author":"Russo","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026071011565657600_ezaf243-B117","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/jcdd10030112","article-title":"Role of antiplatelet therapy in patients with severe coronary artery disease undergoing coronary artery endarterectomy within coronary artery bypass surgery","volume":"10","author":"Balaj","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026071011565657600_ezaf243-B118","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/17425255.2023.2266384","article-title":"Clinical pharmacology of selatogrel for selfadministration by patients with suspected acute myocardial infarction","volume":"19","author":"Gehin","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026071011565657600_ezaf243-B119","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B120","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/ehjcvp\/pvae018","article-title":"GPVI inhibition: advancing antithrombotic therapy in cardiovascular disease","volume":"10","author":"Slater","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026071011565657600_ezaf243-B121","doi-asserted-by":"publisher","first-page":"107630","DOI":"10.1016\/j.pharmthera.2020.107630","article-title":"Glycoprotein VI\u2014novel target in antiplatelet medication","volume":"217","author":"Borst","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2026071011565657600_ezaf243-B122","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","article-title":"Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026071011565657600_ezaf243-B123","doi-asserted-by":"publisher","first-page":"26665","DOI":"10.1074\/jbc.M602174200","article-title":"PAR4, but not PAR1, signals human platelet aggregation via ca2 + mobilization and synergistic P2Y12 receptor activation","volume":"281","author":"Holinstat","year":"2006","journal-title":"J Biol Chem"},{"key":"2026071011565657600_ezaf243-B124","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071011565657600_ezaf243-B125","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1161\/ATVBAHA.123.320448","article-title":"PAR4 antagonism in patients with coronary artery disease receiving antiplatelet therapies","volume":"44","author":"Nash","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071011565657600_ezaf243-B126","doi-asserted-by":"publisher","first-page":"410","DOI":"10.21037\/atm.2019.08.08","article-title":"Targeting ticagrelor: a novel therapy for emergency reversal","volume":"7","author":"Cave","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026071011565657600_ezaf243-B127","doi-asserted-by":"publisher","first-page":"EVIDoa2100047","DOI":"10.1056\/EVIDoa2100047","article-title":"Bentracimab for ticagrelor reversal in patients undergoing urgent surgery","volume":"1","author":"Bhatt","year":"2022","journal-title":"NEJM Evid"},{"key":"2026071011565657600_ezaf243-B128","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"2026071011565657600_ezaf243-B129","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"Duga","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"2026071011565657600_ezaf243-B130","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"2026071011565657600_ezaf243-B131","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1182\/bloodadvances.2017015123","article-title":"Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency","volume":"2","author":"Gidley","year":"2018","journal-title":"Blood Adv"},{"key":"2026071011565657600_ezaf243-B132","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026071011565657600_ezaf243-B133","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ehjcvp\/pvad034","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","volume":"9","author":"Tamargo","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026071011565657600_ezaf243-B134","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/ehjcvp\/pvaf012","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024","volume":"11","author":"Tamargo","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026071011565657600_ezaf243-B135","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ehjcvp\/pvae013","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023","volume":"10","author":"Tamargo","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/67\/8\/ezaf243\/64161152\/ezaf243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/67\/8\/ezaf243\/64161152\/ezaf243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:57:04Z","timestamp":1783699024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezaf243\/8243960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":135,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezaf243","relation":{},"ISSN":["1873-734X"],"issn-type":[{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8]]},"article-number":"ezaf243"}}